Objective： To investigate the expression lose rates of two kinds different RASSF1 transcripts RASSF1A, RASSF1B in gastric-carcinoma and benign gastric disease and discuss their relations to clinical significance. Met...Objective： To investigate the expression lose rates of two kinds different RASSF1 transcripts RASSF1A, RASSF1B in gastric-carcinoma and benign gastric disease and discuss their relations to clinical significance. Methods： The mRNA expressions of RASSF1A and RASSF1B were detected by RT-PCR in 32 patients with gastric-carcinoma, 32 with adjacent non-carcinomatous gastric tissues and 51 cases with benign gastric disease （include 30 chronic shallow gastritis and 21 chronic atrophic gastritis）. Results： The rates of expression loss of transcripts A and B in gastric-carcinoma were 59.3% （19/32） and 28.2% （9/32）, 10% （3/30） and 6.7% （2/30）in chronic shallow gastritis （CSG）, 28.6% （6/21） and 14.3% （3/21） in chronic atrophic gastritis （CAG）, respectively. The rates of expression loss of transcripts A and B in adjacent non-carcinomatous were 0. RASSF 1A and RASSF 1B mRNA expressions had no statistical relations with different grade of gastric- carcinoma. Conclusion： The two different RASSF1 transcripts RASSF1A and RASSF1B were almost expressed in adjacent non-carcinomatous gastric tissues. RASSF1A had a significant expression loss in gastric-carcinoma, and has no statistical relation with different grade of gastric-carcinoma. The result indicated that RASSF1A was a suppressor gene.展开更多
文摘Objective： To investigate the expression lose rates of two kinds different RASSF1 transcripts RASSF1A, RASSF1B in gastric-carcinoma and benign gastric disease and discuss their relations to clinical significance. Methods： The mRNA expressions of RASSF1A and RASSF1B were detected by RT-PCR in 32 patients with gastric-carcinoma, 32 with adjacent non-carcinomatous gastric tissues and 51 cases with benign gastric disease （include 30 chronic shallow gastritis and 21 chronic atrophic gastritis）. Results： The rates of expression loss of transcripts A and B in gastric-carcinoma were 59.3% （19/32） and 28.2% （9/32）, 10% （3/30） and 6.7% （2/30）in chronic shallow gastritis （CSG）, 28.6% （6/21） and 14.3% （3/21） in chronic atrophic gastritis （CAG）, respectively. The rates of expression loss of transcripts A and B in adjacent non-carcinomatous were 0. RASSF 1A and RASSF 1B mRNA expressions had no statistical relations with different grade of gastric- carcinoma. Conclusion： The two different RASSF1 transcripts RASSF1A and RASSF1B were almost expressed in adjacent non-carcinomatous gastric tissues. RASSF1A had a significant expression loss in gastric-carcinoma, and has no statistical relation with different grade of gastric-carcinoma. The result indicated that RASSF1A was a suppressor gene.
